Egalet Corporation announced that members of the Egalet clinical and development teams will be presenting at two upcoming conferences.
WAYNE, Pa., March 21, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) (“Egalet”), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that members of the Egalet clinical and development teams will be presenting at two upcoming conferences. The presentations are as follows:
- Karsten Lindhardt, Ph.D., Egalet’s chief scientific officer, will present “The Guardian™ Technology - Injection Molding of Tablets” tomorrow, March 22, at the SMi 15th Annual Controlled Release Delivery Conference in London, England. Dr. Lindhardt will present on the second day of the two-day conference during the key note address at 11:40 local time.
- Colville Brown, M.D., Egalet medical director, will present at the Insight Exchange Network Conference titled, “Responding to the Opioid Crisis: Litigation, Regulation, & Reform” in Philadelphia, PA on April 16 and 17, 2018. Dr. Brown will present “How is Pharma Responding to the Opioid Crisis? Regulation and Alternative Updates” on April 16 at 3:00 p.m. EDT.
For more information about the SMi conference, visit https://www.smi-online.co.uk/pharmaceuticals/uk/controlled-release and for the Insight Exchange Network conference, please visit https://www.insightxnetwork.com/responding-to-the-opioid-crisis.html.
About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO® ER (morphine sulfate) extended-release tablets for oral use --CII, developed using Egalet’s proprietary Guardian™ Technology, OXAYDO® (oxycodone HCI, USP) tablets for oral use only --CII and SPRIX® (ketorolac tromethamine) Nasal Spray. Using Guardian Technology, Egalet has developed a pipeline of clinical-stage, product candidates for which we are seeking partners including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles.
For full prescribing information on ARYMO ER, including the boxed warning and medication guide, please visit arymoer.com. For full prescribing information on SPRIX, including the boxed warning and medication guide, please visit sprix.com. For full prescribing information on OXAYDO, including the boxed warning and medication guide, please visit oxaydo.com.
